Compare Expedia Group Inc (EXPE) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expedia Group Inc vs Moderna, Inc. — how do they compare? Expedia Group Inc trades at $317.86 (market cap $38.53B), while Moderna, Inc. trades at $62.14 (market cap $24.18B). The key difference: Expedia Group Inc is the larger of the two by market cap, and Expedia Group Inc pays a 0.6% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| EXPE | MRNA | |
|---|---|---|
Market Cap | $38.53B | $24.18B |
Sector | Consumer Cyclical | Health |
52-Week High | $321.07 | $81.80 |
52-Week Low | $188.51 | $22.36 |
Enterprise Value | $37.09B | $20.33B |
Dividend Yield | 0.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expedia Group (EXPE) trades at $314.01, up 1.07% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with Q2 2026 EPS of $5.76 beating estimates by 10.3% and revenue growth accelerating to 14% year-over-year. Recent earnings show continued B2B momentum and AI-driven efficiency improvements, with the company raising full-year revenue guidance to $16.05-16.22 billion. Valuation metrics remain reasonable with P/E of 20.19 and EV/EBITDA of 10.04, while profitability metrics show impressive ROE of 199.12% and net margin of 12.97%.
Expedia presents a favorable investment case with strong earnings momentum, strategic AI integration, and upward guidance revisions. The stock trades near analyst consensus target of $322.95 with 47% buy ratings, though RSI levels suggest potential near-term overbought conditions. Key risks include travel demand sensitivity to economic conditions and competitive pressures in online travel. The combination of fundamental strength and technical momentum supports a constructive outlook for patient investors.
Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.
Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
